Lista de obras -

A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors

scientific article published on 17 October 2019

A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation

scientific journal article

A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs

artículo científico publicado en 2010

Actions of Agonists and Antagonists of the ghrelin/GHS-R Pathway on GH Secretion, Appetite, and cFos Activity.

artículo científico publicado en 2013

Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.

artículo científico publicado en 2012

Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1

artículo científico publicado en 2011

Adropin Deficiency Is Associated With Increased Adiposity and Insulin Resistance ⬇️

artículo científico publicado el 9 de febrero de 2012

Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.

artículo científico publicado en 2009

BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas

artículo científico publicado en 2017

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

artículo científico publicado en 2012

Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.

artículo científico publicado en 2013

Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease.

artículo científico publicado en 2010

Constitutive somatostatin receptor activity determines tonic pituitary cell response.

scientific article published on 08 January 2009

Cortistatin attenuates inflammatory pain via spinal and peripheral actions.

artículo científico publicado en 2013

Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation.

artículo científico publicado en 2013

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

artículo científico publicado en 2002

Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.

artículo científico publicado en 2009

Discovery of Adamantyl Heterocyclic Ketones as Potent 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitors ⬇️

artículo científico publicado el 23 de mayo de 2011

Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.

artículo científico publicado en 2010

Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.

artículo científico publicado en 2008

Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

artículo científico publicado en 2005

Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.

artículo científico publicado en 2005

Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?

artículo científico publicado en 2006

Effect of ghrelin and its analogues, BIM‐28131 and BIM‐28125, on the expression of myostatin in a rat heart failure model ⬇️

artículo científico publicado el 18 de septiembre de 2012

Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation

artículo científico publicado en 2006

Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors

artículo científico publicado en 2019

Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas

artículo científico publicado en 2007

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.

artículo científico publicado en 2008

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

artículo científico publicado en 2005

Endogenous ghrelin regulates episodic growth hormone (GH) secretion by amplifying GH Pulse amplitude: evidence from antagonism of the GH secretagogue-R1a receptor.

artículo científico publicado en 2005

Evidence for Differential Effects of Selective Somatostatin Receptor Subtype Agonists on α-Subunit and Chromogranin A Secretion and on Cell Viability in Human Nonfunctioning Pituitary Adenomasin Vitro

artículo científico publicado en 2004

Evolving concepts in the quest for advanced therapeutic analogues of somatostatin.

artículo científico publicado en 2004

Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.

artículo científico publicado en 2004

Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.

artículo científico publicado en 2003

GHS-1a agonists that effectively stimulate food intake and body weight gain.

artículo científico publicado en 2009

Ghrelin and obestatin modulate growth hormone-releasing hormone release and synaptic inputs onto growth hormone-releasing hormone neurons.

artículo científico publicado en 2011

Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.

artículo científico publicado en 2007

Ghrelin, peptide YY and their hypothalamic targets differentially regulate spontaneous physical activity

artículo científico publicado en 2011

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.

artículo científico publicado en 2007

Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes

artículo científico publicado en 2000

Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin.

artículo científico publicado en 2008

Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism.

artículo científico publicado en 2008

In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists

scientific article published on 01 September 2007

In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines

artículo científico publicado en 2017

In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.

artículo científico publicado en 2015

In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters

artículo científico publicado en 2015

Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5

artículo científico publicado en 1999

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature

scientific article published on 01 October 2018

Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.

artículo científico publicado en 2009

Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.

artículo científico publicado en 2003

New peptide-based therapies for metabolic diseases

scientific article published on 16 April 2008

No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure

scientific article published on 23 August 2008

Novel analogs of ghrelin: physiological and clinical implications

scientific article published on 01 August 2004

Novel chimeric somatostatin analogs: facts and perspectives.

artículo científico publicado en 2007

Novel ghrelin analogs with improved affinity for the GH secretagogue receptor stimulate GH and prolactin release from human pituitary cells

artículo científico publicado en 2004

Novel melanocortin-4 receptor agonists that decrease food intake and body weight.

artículo científico publicado en 2009

Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways.

artículo científico publicado en 2006

PYY3-36 as an anti-obesity drug target.

artículo científico publicado en 2005

Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas.

artículo científico publicado en 2007

Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131

artículo científico publicado en 2014

Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.

artículo científico publicado en 2015

Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient

artículo científico publicado en 2007

Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues

scientific article published on 28 August 2006

Regulation of prostate cancer cell proliferation by somatostatin receptor activation.

artículo científico publicado en 2009

Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

artículo científico publicado en 2016

Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.

artículo científico publicado en 2006

Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.

artículo científico publicado en 2006

Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.

artículo científico publicado en 2007

Somatostatin analogs for the treatment of neuroendocrine tumors.

artículo científico publicado en 2011

Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.

artículo científico publicado en 2005

Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.

artículo científico publicado en 2010

Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas

artículo científico publicado en 2006

Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP.

artículo científico publicado en 2012

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

artículo científico publicado en 2003

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors ⬇️

artículo científico publicado el 1 de noviembre de 1997

Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion

artículo científico publicado en 2003

Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line

artículo científico publicado en 2002

Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion.

artículo científico publicado en 2005

Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2.

artículo científico publicado en 2008

Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors.

artículo científico

Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.

artículo científico publicado en 2004

Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.

artículo científico publicado en 2003

The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells.

artículo científico publicado en 2013

The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness

artículo científico publicado en 2017

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.

artículo científico publicado en 2017

The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.

artículo científico publicado en 2005

The toxicology of chemokine inhibition.

artículo científico publicado en 2005

The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer

artículo científico publicado en 2014

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients

artículo científico publicado en 2016

Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas

artículo científico publicado en 2015

Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor.

artículo científico publicado en 2006

Lista de obras de

A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors

A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation

A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs

Actions of Agonists and Antagonists of the ghrelin/GHS-R Pathway on GH Secretion, Appetite, and cFos Activity.

Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.

Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1

Adropin Deficiency Is Associated With Increased Adiposity and Insulin Resistance ⬇️

Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.

BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.

Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease.

Constitutive somatostatin receptor activity determines tonic pituitary cell response.

Cortistatin attenuates inflammatory pain via spinal and peripheral actions.

Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation.

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.

Discovery of Adamantyl Heterocyclic Ketones as Potent 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitors ⬇️

Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.

Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.

Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.

Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?

Effect of ghrelin and its analogues, BIM‐28131 and BIM‐28125, on the expression of myostatin in a rat heart failure model ⬇️

Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation

Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors

Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

Endogenous ghrelin regulates episodic growth hormone (GH) secretion by amplifying GH Pulse amplitude: evidence from antagonism of the GH secretagogue-R1a receptor.

Evidence for Differential Effects of Selective Somatostatin Receptor Subtype Agonists on α-Subunit and Chromogranin A Secretion and on Cell Viability in Human Nonfunctioning Pituitary Adenomasin Vitro

Evolving concepts in the quest for advanced therapeutic analogues of somatostatin.

Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.

Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.

GHS-1a agonists that effectively stimulate food intake and body weight gain.

Ghrelin and obestatin modulate growth hormone-releasing hormone release and synaptic inputs onto growth hormone-releasing hormone neurons.

Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.

Ghrelin, peptide YY and their hypothalamic targets differentially regulate spontaneous physical activity

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.

Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes

Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin.

Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism.

In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists

In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines

In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.

In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters

Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature

Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.

Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.

New peptide-based therapies for metabolic diseases

No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure

Novel analogs of ghrelin: physiological and clinical implications

Novel chimeric somatostatin analogs: facts and perspectives.

Novel ghrelin analogs with improved affinity for the GH secretagogue receptor stimulate GH and prolactin release from human pituitary cells

Novel melanocortin-4 receptor agonists that decrease food intake and body weight.

Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways.

PYY3-36 as an anti-obesity drug target.

Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas.

Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131

Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.

Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient

Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues

Regulation of prostate cancer cell proliferation by somatostatin receptor activation.

Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.

Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.

Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.

Somatostatin analogs for the treatment of neuroendocrine tumors.

Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.

Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.

Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas

Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP.

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors ⬇️

Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion

Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line

Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion.

Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2.